3D Medicines Inc. (HKG:1244)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
4.080
-0.160 (-3.77%)
At close: Feb 13, 2026
Market Cap1.00B +33.5%
Revenue (ttm)491.34M -8.3%
Net Income-184.64M
EPS-0.75
Shares Out245.39M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume69,000
Average Volume101,825
Open4.230
Previous Close4.240
Day's Range4.060 - 4.230
52-Week Range2.710 - 10.020
Beta0.36
RSI31.64
Earnings DateMar 27, 2026

About 3D Medicines

3D Medicines Inc., a biopharmaceutical company, researches, develops, and commercializes oncology products and other drug candidates for the treatment of patients with various cancers in the People’s Republic of China. The company offers Envafolimab, a PD-L1 antibody in the form of subcutaneous injection for the treatment of previously treated microsatellite instability-high (MSI-H)/mismatch repair deficient(dMMR) advanced solid tumors. It is also developing Envafolimab, which is in Phase III clinical trials for advanced BTC and NSCLC; and in P... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Employees 183
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 1244
Full Company Profile

Financial Performance

In 2024, 3D Medicines's revenue was 445.65 million, a decrease of -29.81% compared to the previous year's 634.95 million. Losses were -182.66 million, -65.19% less than in 2023.

Financial numbers in CNY Financial Statements